Mark Albertini Selected Research

1,24-dihydroxyvitamin D2

12/2015

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Albertini Research Topics

Disease

5	Melanoma (Melanoma, Malignant) 01/2018 - 06/2005
2	Fatigue 12/2015 - 12/2008
2	Neoplasms (Cancer) 12/2015 - 12/2008
1	Urinary Tract Infections (Urinary Tract Infection) 12/2015
1	Neuroblastoma 09/2009
1	Vomiting 12/2008
1	Headache (Headaches) 12/2008
1	Nausea 12/2008
1	Anorexia 12/2008
1	Fever (Fevers) 12/2008
1	Neoplasm Metastasis (Metastasis) 10/2006
1	Disease Progression 06/2005

Drug/Important Bio-Agent (IBA)

2	Bortezomib (Velcade)FDA Link 07/2010 - 06/2005
1	Messenger RNA (mRNA)IBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	VemurafenibIBA 01/2018
1	Insulin-Like PeptidesIBA 01/2018
1	1,24-dihydroxyvitamin D2IBA 12/2015
1	Alkaline PhosphataseIBA 12/2015
1	Vitamin D FDA LinkGeneric 12/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2010
1	Carboplatin (JM8)FDA LinkGeneric 07/2010
1	lorukafusp alfaIBA 09/2009
1	volociximabIBA 12/2008
1	Integrin alpha5beta1IBA 12/2008
1	Indicators and Reagents (Reagents)IBA 10/2006
1	Proteasome InhibitorsIBA 06/2005

Therapy/Procedure

1	Therapeutics 01/2018
1	Drug Therapy (Chemotherapy) 07/2010
1	Adrenalectomy 10/2006